Targeting FGFR3 alterations with adjuvant infigratinib in invasive urothelial carcinoma: The phase III PROOF 302 trial

Sumanta K. Pal, Diederik M. Somford, Petros Grivas, Srikala S. Sridhar, Shilpa Gupta, Joaquim Bellmunt, Guru Sonpavde, Mark T. Fleming, Seth P. Lerner, Yohann Loriot, Jean Hoffman-Censits, Begoña P. Valderrama, Corina Andresen, Marco J. Schnabel, Suzanne Cole, Siamak Daneshmand

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

PROOF 302 is an ongoing randomized, double-blind, placebo-controlled, adjuvant phase III trial (NCT04197986) in approximately 218 patients from 120 centers worldwide. Eligibility criteria include post-surgical high-risk muscle-invasive upper tract urothelial cancer (85% of patients) or urothelial bladder cancer (15%), susceptible FGFR3 alterations (activating mutations, gene fusions or rearrangements), ≤120 days following radical surgery and ineligible for/or refusing cisplatin-based (neo)adjuvant chemotherapy. Patients receive either oral infigratinib 125 mg or placebo daily on days 1-21 of a 28-day cycle for up to 52 weeks or until recurrence, unacceptable toxicity or death. Primary end point: centrally determined disease-free survival (DFS); secondary end points: investigator-assessed DFS, metastasis-free survival, overall survival and safety/tolerability; exploratory end points: correlative biomarker analysis, quality-of-life and infigratinib pharmacokinetics.

Original languageEnglish (US)
Pages (from-to)2599-2614
Number of pages16
JournalFuture Oncology
Volume18
Issue number21
DOIs
StatePublished - Jul 2022
Externally publishedYes

Keywords

  • adjuvant cisplatin-based chemotherapy
  • adjuvant therapy
  • cisplatin-therapy refusal
  • FGFR inhibitor
  • FGFR3
  • fusions or rearrangements
  • infigratinib
  • muscle-invasive urothelial carcinoma
  • mutations
  • neoadjuvant cisplatin-based chemotherapy
  • phase III
  • PROOF 302
  • upper tract urothelial carcinoma
  • urothelial bladder carcinoma
  • urothelial carcinoma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Targeting FGFR3 alterations with adjuvant infigratinib in invasive urothelial carcinoma: The phase III PROOF 302 trial'. Together they form a unique fingerprint.

Cite this